Skip to Main Content

SAN DIEGO — People get excited about gene therapy for the potential to cure some pretty horrible diseases, but the safety risks that patients take on with the preparation and administration of these treatments are often overlooked.

On Saturday afternoon, Bluebird Bio (BLUE) reported for the first time the diagnosis of myelodysplastic syndrome (MDS), a cancer-like disease of the bone marrow, in a single sickle cell disease patient who had undergone treatment with the biotech’s Lentiglobin gene therapy.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.